MedDataX Logo

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT ID: NCT02106923

Last Updated: 2017-03-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220

Healthy
COMPLETED PHASE1

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

NCT02821910

Healthy
COMPLETED PHASE1

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

NCT01002807

Type 2 Diabetes Mellitus (T2DM)
COMPLETED PHASE1

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

NCT02266472

Healthy
COMPLETED PHASE1

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

NCT01211197

Diabetes Mellitus, Type 2
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High dose, fasted

1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions

Group Type EXPERIMENTAL

10 mg Empagliflozin/1000 mg Metformin XR

Intervention Type DRUG

Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

1 tablet Empagliflozin/2 tablets Metformin XR

Intervention Type DRUG

Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

High dose, fed

1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions

Group Type EXPERIMENTAL

1 tablet Empagliflozin/2 tablets Metformin XR

Intervention Type DRUG

Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

10 mg Empagliflozin/1000 mg Metformin XR

Intervention Type DRUG

Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

Low dose, fasted

2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions

Group Type EXPERIMENTAL

1 tablet 10 mg Empagliflozin/3 tablets Metformin XR

Intervention Type DRUG

Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets

2 tablets 5 mg Empagliflozin/750 Metformin XR

Intervention Type DRUG

Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1 tablet Empagliflozin/2 tablets Metformin XR

Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

Intervention Type DRUG

10 mg Empagliflozin/1000 mg Metformin XR

Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

Intervention Type DRUG

1 tablet 10 mg Empagliflozin/3 tablets Metformin XR

Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets

Intervention Type DRUG

2 tablets 5 mg Empagliflozin/750 Metformin XR

Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets

Intervention Type DRUG

1 tablet Empagliflozin/2 tablets Metformin XR

Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

Intervention Type DRUG

10 mg Empagliflozin/1000 mg Metformin XR

Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy males or females
2. Age 18-50 years (incl.)
3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
4. Subjects must be able to understand and comply with study requirements

Exclusion Criteria

Any deviation from healthy condition
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role collaborator

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1276.14

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
NCT02230995 COMPLETED PHASE1
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
NCT02102932 COMPLETED PHASE1
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
NCT03629054 COMPLETED PHASE1
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
NCT03259490 COMPLETED PHASE1
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
NCT01811953 COMPLETED PHASE1
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets
NCT01845077 COMPLETED PHASE1
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
NCT03138356 COMPLETED PHASE1
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
NCT01725672 TERMINATED PHASE1
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
NCT02637037 COMPLETED PHASE1
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.
NCT02084056 COMPLETED PHASE1
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
NCT02071368 COMPLETED PHASE1
The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
NCT03216278 COMPLETED PHASE1
Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects
NCT02173639 COMPLETED PHASE1
Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects
NCT02223026 COMPLETED PHASE1
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
NCT01649297 COMPLETED PHASE2
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
NCT02865668 COMPLETED PHASE1
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
NCT01719003 COMPLETED PHASE3
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
NCT07213895 COMPLETED PHASE1
Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers
NCT01216397 COMPLETED PHASE1
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
NCT02073227 COMPLETED PHASE1
A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
NCT05083949 COMPLETED PHASE1
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets
NCT02028767 COMPLETED PHASE1
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
NCT07266766 COMPLETED PHASE1
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
NCT02077803 COMPLETED PHASE1
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers
NCT02221401 COMPLETED PHASE1